Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Tenaya Therapeutics $50 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
Immunocore Holdings $402.5 million convertible notes offering
The 2.5% convertible notes are due 2030
Greenway Health $375 million refinancing
We advised the administrative agent, arrangers and bookrunners on the financing
Immatics $201 million follow-on offering
We advised Immatics on the offering of shares
IDEAYA Biosciences $350 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Alector $75 million stock offering
The common stock is listed on the Nasdaq Global Select Market